Article Text

Download PDFPDF
Subthreshold laser therapy for macular oedema from branch retinal vein occlusion: focused review
  1. Victor Albert Eng,
  2. Theodore Leng
  1. Byers Eye Institute at Stanford, Stanford University School of Medicine, Palo Alto, California, USA
  1. Correspondence to Theodore Leng, Byers Eye Institute at Stanford, Stanford University School of Medicine, Palo Alto, CA 94303, USA; tedleng{at}stanford.edu

Abstract

Retinal vein occlusion is the second-leading cause of vision loss by retinal vascular disease. Subthreshold micropulse laser therapy (SLT) is safer than conventional laser photocoagulation (CLP), yet existing reviews of its use for branch retinal vein occlusion (BRVO) are limited in scope. A literature search of PubMed, Google Scholar, Embase, Cochrane Library and ClinicalTrials.gov databases was conducted in August 2019 without restriction on language or publication date. Outcomes included changes in macular oedema (ME) and visual acuity (VA), and rates of complications or retreatments. Fourteen studies involving 315–405 eyes diagnosed with BRVO were evaluated. Treatment with SLT is associated with significant and durable reduction of ME and VA as early as 1 month. SLT performs comparably with conventional photocoagulation and intravitreal injections (IVIs) of ranibizumab. Subthreshold laser therapy is safer and as effective as CLP for the treatment of ME associated with BRVO. SLT may be used in combination with anti-VEGF IVIs to enhance improvement in VA and ME resolution.

  • imaging
  • macula
  • retina
  • treatment lasers
  • vision
View Full Text

Statistics from Altmetric.com

Footnotes

  • Twitter @tedleng

  • Contributors VAE participated in the research design, data acquisition/research execution, data analysis/interpretation and manuscript preparation. TL participated in the research design, data analysis/interpretation,and manuscript preparation.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.